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There is an expanding area of small molecule discovery,
especially in the area of peptide mimetics. Peptide
sequences can be used to substitute for the entire native
antigen for use in diagnostic assays. Our approach is to
select peptides that mimic epitopes of the natural immune
response to Epstein–Barr virus (EBV) that may be recog-
nised by antibodies typically produced after infection with
EBV. We screened a random peptide library on sera from
rabbits immunised with a crude preparation of EBV and
serum antibodies from a patient with a high titer of EBV
antibodies. We selected four peptides (Eb1–4) with the
highest relative binding afﬁnity with immune rabbit sera
and a single peptide with high afﬁnity to human serum
antibodies. The peptides were coupled to the carrier
molecule BSA and the recognition of the peptides by IgM
antibodies in clinical samples after infection with EBV was
measured. The sensitivities were Eb1 94%, Eb2, 3, 4 88%,
H1 81% and all had 100% speciﬁcity. This study illustrates
that the phage display approach to select epitope mimics
can be applied to polyclonal antibodies and peptides that
represent several diagnostically important epitopes can be
selected simultaneously. This panel of EBV peptides repre-
senting a wide coverage of immunodominant epitopes
could replace crude antigen preparations currently used
for capture in commercial diagnostic tests for EBV.
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Introduction
Epstein–Barr virus (EBV) or human herpesvirus 4 was
established as the major cause of infectious mononucleosis
commonly known as glandular fever (Epstein and Achong,
1973). The virus has also been linked to more severe diseases
and is associated with severe infection in post-transplantation
and immunocompromised individuals and some malignan-
cies, including Burkitt’s lymphoma, nasopharyngeal carci-
noma, Hodgkin’s disease and immunoblastic lymphoma.
More recently, EBV infection was linked with autoimmune
diseases such as systemic lupus erythematosus (Gross et al.,
2005). There is currently a spectrum of diagnostic strategies
(immunoﬂuorescence assay, western blot, PCR and ELISA;
reviewed by Hess, 2004), but there is no single standardised
diagnostic test for EBV infection to date. Therefore, the
search for a reliable routine diagnostic test is an important
area for investigation. Current commercial serological diag-
nostic tests use ELISA to measure IgG and IgM antibodies
to viral antigens, including viral capsid antigen (VCA), p18
an immunodominant region of VCA (Chan et al., 1998),
EBV nuclear antigens (EBNA) and early antigen (EA-D);
usually, a combination of these tests is required to conﬁrm
acute infections (Gartner et al., 2003).
Our aim in this study is to produce a panel of peptide
mimics, which represent diagnostically important EBV epi-
topes. Our strategy is to ﬁnd alternatives to the authentic EBV
crude antigen used in current commercial ELISA-based tests.
The use of these peptides could provide a more speciﬁc and
cost-effective commercial diagnostic test. Peptides may also
eliminate the high proportion of unwanted epitopes rep-
resented in the crude antigen preparation which can often
result in false-positive cross-reactions. Cross-reactivity with
rheumatoid factor and other herpes viruses has been described
in serological EBV diagnostics (Gartner et al., 2003).
A peptide mimotope or epitope mimic is a peptide that
will mimic the antibody binding site on the antigen and
compete with the native protein for binding. Therefore,
peptide mimotopes representing antigenic epitopes that are
recognised by serum antibodies produced after infection with
EBV may eliminate the need to use the whole antigen in
diagnostic assays.
We have previously generated EBV peptide mimotopes by
identifying peptides against four different monoclonal anti-
bodies from a phage-displayed random peptide library (Casey
et al., 2006; Tschiggerl et al., 2008). These peptides were
found to represent different EBV epitopes and were useful for
detection of EBV IgM antibodies in clinical samples with
100% speciﬁcity and 54–88% sensitivity. Two of the most
effective peptides F1 and Gp125 were subsequently conju-
g a t e dt oB S Aa n du s e di ns c r e e n i n go f.200 EBV serum
samples which resulted in improved sensitivity (95% and
92%; Casey et al., 2006). A limitation of this approach,
however, is that individual mAbs represent only a fraction of
the total antibody response to antigen, whereas the use of
polyclonal antibodies is likely to increase the chances of
selecting useful mimotopes as it samples the entire population
of antibodies in the serum. MAbs are not always available for
every infectious disease agent necessitating the use of polyclo-
nal reagents in these cases. Furthermore, the antibodies in the
polyclonal immune response will react with all the immunodo-
minant epitopes associated with EBV virus infection.
The aim in this study was to select peptide mimics speciﬁc
for epitopes in polyclonal sera from our phage-displayed
peptide library. These peptides may be useful for detecting
antibodies reactive with cognate antigen diagnostically. In
this current study, we have chosen two different approaches
for selection of peptide ligands using polyclonal sera. First,
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high titer of EBV antibodies. Second, we immunised a rabbit
with EBV and afﬁnity-puriﬁed antibodies.
In this study, we show that polyclonal antibodies can be
used to select peptide ligands from a random peptide library
and these epitope mimics are useful for diagnosis, with a
speciﬁcity and sensitivity similar to those peptide mimics
selected against EBV mAbs described in our previous study
(Casey et al., 2006). This study is also the ﬁrst example of
screening a random peptide library with polyclonal anti-
bodies from an immunised rabbit and has allowed isolation
of peptide mimotopes to several important diagnostic epi-
topes simultaneously.
Materials and methods
Preparation of polyclonal EBV antisera
A New Zealand white rabbit was immunised intramuscularly
with 200 mg EBV-infected cell extract (crude EBV; ABI,
MD, USA) emulsiﬁed in 0.5 ml Freund’s complete adjuvant.
Two booster doses diluted 1:1 in Freund’s incomplete adju-
vant followed by a ﬁnal double-dose boost were performed
in 21 day intervals.
Human serum samples
A panel of 40 individual human serum samples were pro-
vided by Queensland Medical Laboratory (Brisbane,
Australia). The positive sera (n ¼ 16) were collected from
individuals with recent or early stage of infectious mononu-
cleosis and were tested for the presence of IgM antibodies to
EBV using a commercial diagnostic test (PanBio Ltd). An
individual seropositive serum sample with a high titer of
IgM and IgG EBV antibodies was selected for puriﬁcation.
The negative sera (n ¼ 16) were collected from patients
having no previous exposure to EBV infection and were
deﬁned as seronegative using the commercial diagnostic test.
Putative cross-reactive sera were also screened (n ¼ 8), two
Parvovirus (Parvo), two Herpes Simplex virus (HSV), two
Cytomegalovirus (CMV) and two Rheumatoid factor (RF),
to analyse the speciﬁcity of binding.
Afﬁnity puriﬁcation of rabbit and human IgG
The IgG fraction from an EBV-immunised rabbit and human
serum with a high titer of antibodies to EBV were puriﬁed
using Protein G sepharose (2.5 ml column; Pharmacia), using
the manufacturer’s instructions. Brieﬂy serum was diluted
1:5 in PBS and passed through a 0.2 mm syringe ﬁlter prior
to being applied to the resin, and antibodies were eluted with
0.1 M glycine pH 3.0, neutralised and dialysed against PBS
with three buffer changes.
Phage library and selection
For selection of phage peptides to afﬁnity puriﬁed sera from
an EBV-infected patient and an EBV-immunised rabbit, we
screened our AdLib 1 library (AdAlta Pty Ltd) a linear
peptide library of 20 random amino acids displayed as
N-terminal fusions to protein III of ﬁlamentous phage M13
(Casey et al., 2004, 2006, 2008). A similar panning strategy
was used as described in our previous study (Casey et al.,
2006). Brieﬂy ELISA wells were coated with 10 mg/ml puri-
ﬁed rabbit or human anti-EBV IgG preparations and peptides
were selected from the library of .5   10
8 random peptides
by performing six rounds of panning. The stringency of
washing was increased in each subsequent round of panning
to enrich for phage peptides that bound speciﬁcally to the
target antibodies.
Peptide synthesis
Peptides were synthesised to .70% purity by GL-Biochem
(Shanghai, China). Peptides Eb1, Eb3 and Eb4 were
dissolved in dimethyl formamide at 1 mg/ml used fresh or
stored in aliquots at –208C. Eb2 was soluble in PBS and
stored in a similar manner. Gp125 and F1 peptides were pre-
pared as previously described (Casey et al., 2006).
Peptide conjugation to BSA
Peptides were synthesised with four additional glycine resi-
dues and an additional cysteine residue at the C0 terminus
(Gly4Cys). The glycines provide a small spacer region
between the peptide and the additional cysteine residue
allows for conjugation to BSA via the heterobifunctional
cross-linker succinimidyl-4-(N-maleimidomethyl)cyclohexane-
1-carboxylate (SMCC, Pierce), using the same method as
described in our previous study (Casey et al., 2006). Brieﬂy
100 molar excess of SMCC was added to 5 mg BSA
(Thermo, New Zealand) in 0.1 M sodium phosphate/0.15 M
sodium chloride buffer for 2 h mixing at room temperature.
To remove excess linker, the mixture was desalted using a
PD-10 column equilibrated with the same buffer containing
0.1 M EDTA. For conjugation, 1 mg of peptide was incu-
bated with 1–2 mg of BSA-SMCC in the presence of 30%
DMSO for 2 h. The ﬁnal BSA-conjugated peptide was
desalted using a PD-10 column into PBS and the concen-
tration of conjugated peptides in column fractions was
measured at 280 nm absorbance using a spectrophotometer.
Phage ELISAs
To analyse the binding of peptide phage clones, ELISAs
were performed by coating a microtiter plate overnight at
48C (Nunc, Maxisorp) with 100 ml/well of 10 mg/ml of puri-
ﬁed rabbit or human polyclonal antibodies in PBS. Coated
wells were washed twice with PBS and blocked with 10%
blotto (milk powder/PBS) for 2 h. Phage dilutions (100 ml)
were prepared in PBS, transferred in duplicate to the coated
blocked wells and incubated for 1 h on a plate shaker. Wells
were washed ﬁve times with PBS containing 0.1% Tween 20
(PBST) and 100 ml of anti-M13 antibody conjugated to
horseradish peroxidase (HRP, Pharmacia) at 1/5000 dilution
was added to each well. After 1 h incubation and washing as
above, bound phages were detected with o-phenylenediamine
substrate (Sigma).
Antigen ELISAs
ELISAs were performed using plates coated with crude
EBV, p18, EBNA, EA-D and VCA antigens (pre-coated and
blocked plates were kindly provided by PanBio Ltd,
Brisbane). Serum dilutions were prepared in ﬁsh gelatin
diluent [2% ﬁsh gelatin (Sigma), 1% BSA (CSL), 1% Tween
20 in PBS] and incubated for 1 h on the plate shaker. The
plate was washed as above and sheep anti-human
IgM-HRP (Chemicon) at 1/5000 dilution was added for
1 h. After a ﬁnal wash step, binding was detected with
3,30,5,50-tetramethylbenzidine substrate (Sigma).
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For ELISAs using peptides conjugated to BSA, a procedure
similar to our previous study was used (Casey et al., 2006).
One hundred microlitres per well of peptide conjugates were
coupled to maxisorp plates at 5 mg / m lo v e r n i g h ta t4 8C. Plates
were washed three times with PBS and serum sample dilutions
in PBST were added to the blocked wells in duplicate. The
remainder of the procedure was performed as above, using
goat anti-rabbit-HRP (Chemicon) at 1/2000 dilution.
All ELISAs were performed in duplicate or triplicate and
assays were repeated to establish reproducibility of results.
Results
Reactivity of rabbit anti-EBV antibodies
The rabbit immunised with an extract of EBV was shown to
have a high titer of antibodies (.1/1000) to p18, crude EBV
and VCA antigens as shown in Fig. 1A, when compared with
the low reactivity of the pre-bleed fraction to these antigens. The
IgG fraction of the antisera was afﬁnity-puriﬁed using protein G
resin and this preparation was used for immunopanning.
Characterisation of EBV human sera
Human serum from an individual with a high titer of EBV
IgG antibodies (OD units in ELISA .2.0) conﬁrmed using
an EBV diagnostic kit (PanBio Ltd) was puriﬁed using
protein G resin. The reactivity of the puriﬁed antibodies is
shown in Fig. 1B. There was high binding to crude EBV and
Fig. 1. Characterisation of EBV immune sera. (A) ELISA showing the
antibody titer of rabbit serum to crude EBV, VCA and p18 antigens before
and after immunisation. (B) Speciﬁcity of human serum tested positive on a
commercial EBV test that has been afﬁnity puriﬁed using Protein G. ELISA
showing reactivity of this human IgG to EBV antigens, crude EBV, VCA,
p18 compared with wells coated with no antigen (no Ag).
Fig. 2. Selection of phage clones that are recognised by (A) rabbit
anti-EBV IgG (Rab IgG) and (B) human anti-EBV IgG (Hu IgG). The
reactivity of selected phages from each round of panning (R) is shown by
ELISA. Error bars indicate the ranges of individual values.
Table I. Peptide sequences of clones selected after 4, 5 or 6 rounds of
panning on immune rabbit and human EBV IgG
Amino acid sequence
DGPSYHVAFKNSRGLRHS H1
a
NGALYPR FFPDYSILMFPII Eb1
a
DQFAQAYRGDRN FFNELTST Eb2
a
RQFSKFKDASDRYGNYLH F F Eb3
a
SSSIKIWNKLGWNTVIAGTR Eb4
a
FVNAFQNANFMRPRELFALA E b 5
SANLN FFSPDFGLYTPNASA E b 6
AITCAHTLSIKSRRCQYVFK E b 7
AASYASRTVGFASVYWFSRP E b 8
RLRGDYNVGPIRFGWPVAPN E b 9
MSDFDRKVYTFNFITDPQHL
b Eb10
GVTDFDFKVFSSTFPKIFLS
b Eb11
TPNTVRDFYYNVSLPSYMLI
b Eb12
GGWYSFDSPYLMSITEMRLR Gp125
c
YTDSSMAVTLMKFASNFLF F1
c
Bold and underlined areas represent areas of homology.
aIndicates peptides selected for further study.
bIndicates binding to pre-immune sera.
cIndicates peptides Gp125 and F1 described previously (Casey et al., 2006).
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87p18 antigens slightly lower binding to VCA antigen, when
compared with ELISA wells containing no antigen. This
antibody preparation was used for immunopanning.
Selection of peptide mimotopes
Peptides mimicking epitopes of anti-EBV rabbit IgG and
anti-EBV human IgG were isolated by screening a 20 amino
acid random linear peptide library (AdLib 1) using multiple
rounds of panning. For selection of phage binding to rabbit
EBV IgG, an increased number of bound phage was detected
after the second round of panning with a further increase in
round 3 and a plateau in binding in rounds 4, 5 and 6
(Fig. 2A). For immunopanning on human EBV IgG, enrich-
ment in binding was observed after the fourth round of
panning, indicated by an increase in binding to antigen and
this increased further in subsequent rounds 5 and 6 (Fig. 2B).
Sequences of phage clones
DNA sequences of 10 clones from each round of panning
with a high ELISA signal, i.e. rounds 4, 5 and 6, are sum-
marised in Table I. Twelve different sequences with high
reactivity with the rabbit EBV IgG fraction were identiﬁed,
whereas only one sequence from a total of 30 clones was iso-
lated that showed the speciﬁcity for the human EBV IgG
preparation. No consensus sequence was observed; however,
a small amount of homology for some of the sequences is
shown in Table I. For example, Eb10 and Eb11 shared a
similar region ‘D FD(R/F) K V’ and Eb12 contained ‘F D
R’ (in reverse orientation). This sequence of amino acids is
contained within the same area of homology shown in bold
type in the reverse orientation. In addition, sequences Eb4
and Eb7 also had a small area of homology, ‘S I K’.
Furthermore, 4/12 sequences contained an ‘F F’ motif.
Characterisation of individual phage clones
Individual phage clones were analysed for reactivity with
pre-immune and immune EBV rabbit IgG antibodies
(Fig. 3). Only 3/12 phage clones were reactive with the pre-
immune IgG indicating the remaining nine clones bind to
EBV-speciﬁc antibodies in the immune sera. The two clones
Eb10 and Eb11 described above with a similar area of hom-
ology ‘D F D (R/F) K V’ were both recognised by antibodies
Fig. 3. Reactivity of rabbit EBV IgG individual phage clones. Clones isolated from rounds 4–6 selected on rabbit EBV IgG were analysed for reactivity with
immune and pre-immune IgG by ELISA. Clones Eb1–4 with the highest binding to immune serum were selected for further study.
Fig. 4. Reactivity of isolated phage clone (H1) selected by panning on
human EBV IgG with the same IgG and a non-speciﬁc human IgG
preparation (A). H1 is recognised by four different afﬁnity puriﬁed
EBV-seropositive IgGs (B), indicating speciﬁcity for a common epitope
typically present in individuals infected with EBV. Bars show the mean
ELISA signal of duplicate wells and the bars indicate þ/2 errors.
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R’ (in reverse orientation) was also recognised by the pre-
immune sera, therefore, indicating these clones are represent-
ing non-EBV-speciﬁc epitopes. The four clones with the
highest reactivity with rabbit EBV immune sera (Eb1–Eb4)
were selected for further study.
The single clone selected from the random peptide library
(H1) with high reactivity with the human IgG EBV prep-
aration was shown to have low reactivity with a control IgG
(Fig. 4A). This observation suggests EBV-speciﬁc antibodies
are reactive with H1 phage. Importantly, antibodies in the
serum of puriﬁed EBV-positive individual sera from four
individuals were reactive with H1, indicating the speciﬁcity
with an epitope common to antibodies present in each of
these positive sera (Fig. 4B).
Eb1–4 and H1 phage clones were not recognised by
mAbs (gp125, F1, A2 and A3; data not shown) described in
our previous study (Casey et al., 2006), suggesting that we
have selected novel peptides that do not mimic similar epi-
topes of these antibodies and therefore should represent
different epitopes that are perhaps speciﬁc to those induced
during a natural EBV infection.
Peptide-BSA conjugates as diagnostic antigens
To analyse the potential of the peptides to behave as antigen
mimics, their ability to react with IgM antibodies from indi-
viduals infected with EBV was assessed. In our previous
study, we demonstrated that the sensitivity of detection was
greatly improved when the peptides were coupled to a carrier
molecule such as BSA prior to immobilisation onto a solid
surface (Casey et al., 2006). This strategy was adopted to test
peptides Eb1–4 and H1. A set of 40 clinical samples that
were classiﬁed as EBV seropositive (n ¼ 16), seronegative
(n ¼ 16) or potentially cross-reactive sera (n ¼ 8) were
assessed for reactivity with Eb1–4 and H1 peptides individu-
ally. The cut-off level was deﬁned as the mean optical
density of the seronegative samples plus 3 standard devi-
ations shown as a line on the graphs in Fig. 5. Readings
above this level were deﬁned as positive and below this level
negative. The same set of samples were analysed on BSA
Fig. 5. Evaluation of peptides Eb1–4 and H1 coupled to BSA as EBV diagnostic reagents. Human serum (n ¼ 40) previously analysed using a diagnostic test
for VCA IgM was allowed to react with the peptides and the bound IgM antibodies were detected using anti-human IgM HRP. The absorbance readings for 1
(positive), 2 (negative) and putative cross-reactive sera for 3 (Parvo), 4 (HSV), 5 (CMV) and 6 (RF) are plotted for (A) Eb1, (B) Eb2, (C) Eb3, (D) Eb4, (E)
H1 and (F) BSA, respectively. The cut-off value is deﬁned as the mean of the negative population þ3SD indicated by a solid horizontal line; since there were
no false positives, the speciﬁcity for each mimotope was 100%.
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peptide-BSA conjugate readings and the corrected absor-
bance readings were plotted individually for our new pep-
tides Eb1–4 and H1 in Fig. 5. There was a clear difference
in the detection of seropositive antibodies by all the peptides
(Fig. 5A–E) compared with the analysis of BSA alone
(Fig. 5F), with the majority of absorbance readings above the
cut-off level. We compared the ability of our panel of
peptide mimotopes to be recognised by antibodies in the
same set of seropositive samples in Fig. 6A and the sensi-
tivity of detection is shown in Fig. 6B. We also included F1
and Gp125 mimotopes speciﬁc for two mAbs in our previous
study (Casey et al., 2006). Of the peptides identiﬁed from
polyclonal sera Eb1, Gp125 and F1 had the highest sensi-
tivity (94%). Slightly lower sensitivity was observed for Eb2,
3 and 4 (88%) and H1 peptide had the lowest sensitivity
(81%) as summarised in Fig. 6B. The sensitivity of F1 and
Gp125 was similar to that produced by the mimotopes
selected in our previous study, 95% for F1 and 92% for
Gp125.
We also considered which seropositive EBV samples con-
tained antibodies that did not recognise the panel of peptides,
i.e. false-negative readings, listed in Fig. 6B. The antibodies
in serum 1 (s1) were unreactive with all of the peptides
identiﬁed in this study, s2 was not reactive with Eb3, Eb4
and H1 and s3 was unreactive with H1. Gp125 and F1 that
were selected in our previous study were recognised by s1, 2
and 3; however, two different serum samples (s4 and 5) did
not recognise F1 or Gp125, respectively. This demonstrates
that individual peptides are not recognised by all EBV anti-
bodies and conﬁrms that different peptides are required to
represent different epitopes. Therefore, a combination of
Eb1 peptide F1 and Gp125 peptides could be recognised by
antibodies present in all this set of EBV clinical samples
resulting in 100% sensitivity.
For the samples deﬁned as EBV-seronegative, there were
no readings above the cut-off level and therefore no false
positives, resulting in 100% speciﬁcity. In addition, there
were no absorbance readings above the cut-off levels for
the potentially cross-reactive serum samples, inferring that
the peptides identiﬁed in this study have high speciﬁcity for
EBV antibodies.
Discussion
We have developed a library screening approach to select
peptides that can substitute for the cognate antigen in assays
used in the diagnosis of acute EBV infection. EBV mimo-
topes were isolated from a phage-displayed peptide library
by screening puriﬁed antibodies derived from polyclonal
human sera and hyperimmune rabbit sera. This novel
approach enables the simultaneous selection of peptides that
mimic different epitopes with no prior knowledge of the
native antigen and is therefore more rapid than selections
using mAbs.
The strategy to select disease-speciﬁc epitope mimics
using immune sera has so far been largely unexplored as
many previous studies in this ﬁeld have employed mAbs to
neutralising or immunodominant epitopes. However, a few
reports have described the use of patients’ sera to identify
peptide mimics. Polyclonal sera has been used to select pep-
tides for Lyme disease (Mathiensen et al., 1998), Hepatitis C
virus core protein (Prezzi et al., 1996) and Hepatitis A virus
(Larralde et al., 2007) and led to the identiﬁcation of
disease-related peptides by screening large numbers of clini-
cal sera from immune and non-immune individuals with no
prior knowledge of the target antigen (Folgori et al., 1994).
More recently, phage display peptide libraries were used to
validate a speciﬁc serological marker and identify the native
antigen by screening antibodies puriﬁed from whole serum
derived from prostate cancer patients (Mintz et al., 2003).
In this study, we have identiﬁed several peptides that can
be used individually for detection of natural antibodies pro-
duced by patients recently infected with EBV. All the pep-
tides demonstrated high speciﬁcity (all 100%) and sensitivity
(94%, 88%, 88%, 88% for Eb1–4 and 81% for H1). As we
have noted previously, these peptides have no obvious hom-
ology to EBV antigens and further studies should be carried
out to identify their corresponding antigens. In addition, the
peptides had low reactivity with negative and putative cross-
reactive sera, indicating the high speciﬁcity of small peptides
for serological diagnosis compared with a complex antigen
Fig. 6. Comparison of the reactivities of our panel of mimotopes Eb1–4,
H1, F1 and Gp125 conjugated to BSA with EBV IgM-positive sera (n ¼ 16)
absorbance values are plotted and the cut-off levels are depicted by a
horizontal line in (A). (B) Summary of the false-negative results from the 5/
16 serum samples seropositive for IgM EBV and the overall sensitivity for
each mimotope for diagnosis of EBV IgM antibodies.
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were used in combination, a greater sensitivity was observed
(up to 100%), indicating this is a requirement for complete
coverage of pathogen-speciﬁc antibodies in the sera of
patients.
The aim of this study was to select peptides that mimic
the most abundant and/or immunodominant epitope present
during a recent infection with EBV. We chose to purify an
individual serum rather than a pool of high titre patient
samples. If a pool was used, these epitopes may have been
diluted making it more difﬁcult to isolate a peptide reactive
with the antibody/s generated by this immunodominant
epitope. We have shown here (Fig. 4) that the peptide mimo-
tope H1 was recognised by antibodies in four different clini-
cal samples, proving that antibodies derived from an
individual seropositive serum can produce a pathogen-
speciﬁc peptide mimic. In order to extend the coverage of
diagnostically relevant epitopes, further selections could be
carried out using a pool of high titer seropositive EBV
samples to decipher whether more peptides could be selected
simultaneously and similarly to the data we have shown in
this study using polyclonal sera from rabbits immunised with
EBV.
In conclusion, we describe in this study a panel of EBV
peptide mimotopes when used in combination are recognised
by the whole repertoire of antibodies typically produced after
acute infection with EBV. This methodology could be
applied to many diseases and may provide novel reagents for
diagnosis and prognosis of diseases and reveal information
regarding unknown pathogenic agents.
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